File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus

TitleAntiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus
Authors
KeywordsAnti-β 2-glycoprotein I antibodies
Anticardiolipin antibodies
Antiphospholipid syndrome
Pregnancy outcome
Thrombosis
Issue Date2005
PublisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
Citation
Journal Of Rheumatology, 2005, v. 32 n. 4, p. 622-628 How to Cite?
AbstractObjective. Different prevalences of antiphospholipid antibodies (aPL) have been reported in different populations of patients with systemic lupus erythematosus (SLE). Chinese are generally believed to have lower risk of vascular thrombosis. We examined the prevalence of aPL including lupus anticoagulant (LAC), anticardiolipin (aCL) and anti-β 2- glycoprotein I (anti-β 2-GPI) antibodies, the level of thrombotic risk, and the association of aPL with thrombotic and pregnancy outcomes in a Chinese cohort with SLE at the university lupus clinic during the period 1986-2003. Methods. aPL were measured in 272 SLE patients, and medical records were reviewed for vascular thrombosis and pregnancy outcomes. Results. The prevalence of LAC, IgG aCL, and IgG anti-β 2-GPI antibodies was 22.4%, 29.0%, and 7.7%, respectively. There were 38 episodes of thrombosis after a mean duration of followup of 11.0 ± 6.8 SD years, giving a thrombotic rate of 1.26/100 patient-years. All aPL were shown to be associated with vascular thrombosis. IgG anti-β 2-GPI antibodies were found to be associated with recurrent thrombosis [8.0/100 patient-years or 25.0% (7/28)]. Patients taking hydroxychloroquine were found to have fewer thrombotic complications than those who were not (OR 0.17, 95% CI 0.07-0.44; p < 0.0001). LAC was the strongest factor associated with recurrent miscarriages [relative risk 12.3, 95% CI 1.22-123.31; p = 0.03). The diagnosis of secondary antiphospholipid syndrome was satisfied in 8.9% of patients. Conclusion. The lifetime and recurrent thrombotic rates in our patients with aPL were not particularly different from those in the literature. However, the lower prevalence of aPL in our cohort may suggest a role of other prothrombotic factors in predisposition to thrombosis.
Persistent Identifierhttp://hdl.handle.net/10722/87609
ISSN
2015 Impact Factor: 3.236
2015 SCImago Journal Rankings: 1.225
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMo, YMen_HK
dc.contributor.authorChan, EYTen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorLeung, KFSen_HK
dc.contributor.authorWoon, SWen_HK
dc.contributor.authorChak, SLen_HK
dc.date.accessioned2010-09-06T09:32:03Z-
dc.date.available2010-09-06T09:32:03Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of Rheumatology, 2005, v. 32 n. 4, p. 622-628en_HK
dc.identifier.issn0315-162Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87609-
dc.description.abstractObjective. Different prevalences of antiphospholipid antibodies (aPL) have been reported in different populations of patients with systemic lupus erythematosus (SLE). Chinese are generally believed to have lower risk of vascular thrombosis. We examined the prevalence of aPL including lupus anticoagulant (LAC), anticardiolipin (aCL) and anti-β 2- glycoprotein I (anti-β 2-GPI) antibodies, the level of thrombotic risk, and the association of aPL with thrombotic and pregnancy outcomes in a Chinese cohort with SLE at the university lupus clinic during the period 1986-2003. Methods. aPL were measured in 272 SLE patients, and medical records were reviewed for vascular thrombosis and pregnancy outcomes. Results. The prevalence of LAC, IgG aCL, and IgG anti-β 2-GPI antibodies was 22.4%, 29.0%, and 7.7%, respectively. There were 38 episodes of thrombosis after a mean duration of followup of 11.0 ± 6.8 SD years, giving a thrombotic rate of 1.26/100 patient-years. All aPL were shown to be associated with vascular thrombosis. IgG anti-β 2-GPI antibodies were found to be associated with recurrent thrombosis [8.0/100 patient-years or 25.0% (7/28)]. Patients taking hydroxychloroquine were found to have fewer thrombotic complications than those who were not (OR 0.17, 95% CI 0.07-0.44; p < 0.0001). LAC was the strongest factor associated with recurrent miscarriages [relative risk 12.3, 95% CI 1.22-123.31; p = 0.03). The diagnosis of secondary antiphospholipid syndrome was satisfied in 8.9% of patients. Conclusion. The lifetime and recurrent thrombotic rates in our patients with aPL were not particularly different from those in the literature. However, the lower prevalence of aPL in our cohort may suggest a role of other prothrombotic factors in predisposition to thrombosis.en_HK
dc.languageengen_HK
dc.publisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.comen_HK
dc.relation.ispartofJournal of Rheumatologyen_HK
dc.subjectAnti-β 2-glycoprotein I antibodiesen_HK
dc.subjectAnticardiolipin antibodiesen_HK
dc.subjectAntiphospholipid syndromeen_HK
dc.subjectPregnancy outcomeen_HK
dc.subjectThrombosisen_HK
dc.subject.meshAbortion, Habitual - complications - ethnology - immunologyen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntibodies, Antiphospholipid - blooden_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHospitals, Universityen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLongitudinal Studiesen_HK
dc.subject.meshLupus Erythematosus, Systemic - complications - ethnology - immunologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPregnancyen_HK
dc.subject.meshPregnancy Complications, Hematologic - ethnology - immunologyen_HK
dc.subject.meshThrombosis - complications - ethnology - immunologyen_HK
dc.titleAntiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0315-162X&volume=32 &issue=4&spage=622&epage=8&date=2005&atitle=Antiphospholipid+Antibody+Profiles+and+Their+Clinical+Associations+in+Chinese+Patients+with+Systemic+Lupus+Erythematosusen_HK
dc.identifier.emailMo, YM: temy@hkucc.hku.hken_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.authorityMo, YM=rp00490en_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid15801016-
dc.identifier.scopuseid_2-s2.0-17144382450en_HK
dc.identifier.hkuros97695en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-17144382450&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume32en_HK
dc.identifier.issue4en_HK
dc.identifier.spage622en_HK
dc.identifier.epage628en_HK
dc.identifier.isiWOS:000228370500010-
dc.publisher.placeCanadaen_HK
dc.identifier.scopusauthoridMo, YM=7006024184en_HK
dc.identifier.scopusauthoridChan, EYT=7401994013en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridLeung, KFS=55177487700en_HK
dc.identifier.scopusauthoridWoon, SW=8617524400en_HK
dc.identifier.scopusauthoridChak, SL=8617524500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats